Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SOMA Compound with Codeine is a fixed-dose combination tablet containing aspirin, carisoprodol, and codeine phosphate, approved in 1960 for oral use. This product combines analgesic (aspirin, codeine), muscle relaxant (carisoprodol), and opioid components to treat acute musculoskeletal pain and associated muscle spasms. The mechanism leverages multiple pathways: aspirin as a non-selective COX inhibitor, carisoprodol as a central muscle relaxant, and codeine as an opioid agonist.
With lifecycle approaching LOE and moderate competitive pressure (30), commercial teams face defensive positioning challenges and potential portfolio reallocation as the product enters decline.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SOMA Compound with Codeine offers limited career growth opportunity given its LOE-approaching lifecycle and zero linked job openings. Roles available are primarily defensive—protecting market share, managing generic transition, and ensuring compliance with opioid stewardship regulations.
Worked on SOMA COMPOUND W/ CODEINE at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.